Undertreatment of elderly patients with non-small-cell lung cancer

Raymond Ng, Richard de Boer*, Michael D. Green

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The absolute number of patients with lung cancer is rising as a result of our aging population. Until recently, clinicians have been reluctant to aggressively treat elderly patients with non-small-cell lung cancer (NSCLC) because of a lack of supportive data and concern for potential toxicity. Recently, evidence has emerged that suggests that, similar to younger patients, healthy elderly patients can benefit from therapy in all stages of NSCLC. This review will discuss the findings that indicate that chronologic age alone should not be a barrier to appropriate treatment for NSCLC, but consideration should be given to more important prognostic factors such as comorbidities and performance status.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalClinical Lung Cancer
Issue number3
StatePublished - Nov 2005
Externally publishedYes


  • Chemotherapy
  • Cisplatin
  • Docetaxel
  • Radiation therapy
  • Vinorelbine


Dive into the research topics of 'Undertreatment of elderly patients with non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this